Hyperuricemia in childhood primary hypertension.
PDF (339K)
Journal: 2004/February - Hypertension
ISSN: 1524-4563
Abstract:
Experimental animal models suggest that uric acid might have a pathogenic role in the early development of primary hypertension. We hypothesized that serum uric acid is correlated with blood pressure in children with new-onset, untreated, primary hypertension. We evaluated 125 consecutive children referred to the Baylor Pediatric Renal Program for evaluation of hypertension. None of the subjects had previously been evaluated or treated for hypertension. The children ranged in age from 6 to 18 years (mean, 13.4+/-3.3) and had normal renal function (creatinine clearance >80 mL x min(-1) x 1.73 m(-2)). Sixty-three children had primary hypertension, 40 had secondary hypertension, and 22 had white-coat hypertension. Forty controls with normal blood pressure were recruited from the renal clinic. Uric acid levels were directly correlated with systolic (r=0.80, P=0.0002) and diastolic (r=0.66, P=0.0006) blood pressure in controls and in subjects with primary hypertension and were independent of renal function. Serum uric acid concentrations >5.5 mg/dL were found in 89% of subjects with primary hypertension, in 30% with secondary hypertension, in 0% with white-coat hypertension, and in 0% of controls. We conclude that serum uric acid is directly correlated with blood pressure in untreated children and that a serum uric acid value >5.5 mg/dL in an adolescent being evaluated for hypertension strongly suggests primary hypertension as opposed to white-coat or secondary hypertension. These results are consistent with the hypothesis that uric acid might have a role in the early pathogenesis of primary hypertension.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(113)
References
(41)
Diseases
(1)
Conditions
(2)
Chemicals
(1)
Organisms
(1)
Processes
(2)
Affiliates
(2)
Similar articles
Articles by the same authors
Discussion board
Hypertension 42(3): 247-252
PMID: 12900431

Hyperuricemia in Childhood Primary Hypertension

Corresponding author.
Reprint requests to Daniel I. Feig, MD, PhD, Baylor College of Medicine, Renal Section, Department of Pediatrics, MC3-2482, 6621 Fannin St, Houston, TX 77030. E-mail ude.cmt.mcb@giefd
Copyright notice

Abstract

Experimental animal models suggest that uric acid might have a pathogenic role in the early development of primary hypertension. We hypothesized that serum uric acid is correlated with blood pressure in children with new-onset, untreated, primary hypertension. We evaluated 125 consecutive children referred to the Baylor Pediatric Renal Program for evaluation of hypertension. None of the subjects had previously been evaluated or treated for hypertension. The children ranged in age from 6 to 18 years (mean, 13.4±3.3) and had normal renal function (creatinine clearance >80 mL · min · 1.73 m). Sixty-three children had primary hypertension, 40 had secondary hypertension, and 22 had white-coat hypertension. Forty controls with normal blood pressure were recruited from the renal clinic. Uric acid levels were directly correlated with systolic (r=0.80, P=0.0002) and diastolic (r=0.66, P=0.0006) blood pressure in controls and in subjects with primary hypertension and were independent of renal function. Serum uric acid concentrations >5.5 mg/dL were found in 89% of subjects with primary hypertension, in 30% with secondary hypertension, in 0% with white-coat hypertension, and in 0% of controls. We conclude that serum uric acid is directly correlated with blood pressure in untreated children and that a serum uric acid value >5.5 mg/dL in an adolescent being evaluated for hypertension strongly suggests primary hypertension as opposed to white-coat or secondary hypertension. These results are consistent with the hypothesis that uric acid might have a role in the early pathogenesis of primary hypertension.

Keywords: uric acid, hypertension, essential, children, renal disease
Abstract

References

  • 1. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler JBlood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18.[PubMed][Google Scholar]
  • 2. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJPrevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994) Arch Intern Med. 2001;161:1207–1216.[PubMed][Google Scholar]
  • 3. Mohamed FAOn chronic Bright's disease, and its essential symptoms. Lancet. 1879;1:399–401.[PubMed][Google Scholar]
  • 4. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JHHyper-uricemia in primary and renal hypertension. N Engl J Med. 1966;275:457–464.[PubMed][Google Scholar]
  • 5. Kinsey D, Walther R, Sise HS, Whitelaw G, Smithwick RIncidence of hyperuricemia in 400 hypertensive subjects. Circulation. 1961;24:972–973.[PubMed][Google Scholar]
  • 6. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HASerum uric acid: its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 1973;132:401–410.[PubMed][Google Scholar]
  • 7. Selby JV, Friedman GD, Quesenberry CP., JrPrecursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990;131:1017–1027.[PubMed][Google Scholar]
  • 8. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, Trevisan MSerum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens. 1994;8:677–681.[PubMed][Google Scholar]
  • 9. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJElevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101–1106.[PubMed][Google Scholar]
  • 10. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJHyper-uricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991–F997.[PubMed][Google Scholar]
  • 11. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan HY, Johnson RJUric acid hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355–360.[PubMed][Google Scholar]
  • 12. Zinner SH, Rosner B, Oh W, Kass EHSignificance of blood pressure in infancy: familial aggregation and predictive effect on later blood pressure. Hypertension. 1985;7(pt 1):411–416.[PubMed][Google Scholar]
  • 13. Lauer RM, Clarke WRChildhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics. 1989;84:633–641.[PubMed][Google Scholar]
  • 14. Berenson GS, Srinivasan SR, Hunter SM, Nicklas TA, Freedman DS, Shear CL, Webber LSRisk factors in early life as predictors of adult heart disease: the Bogalusa Heart Study. Am J Med Sci. 1989;298:141–151.[PubMed][Google Scholar]
  • 15. Burke GL, Arcilla RA, Culpepper WS, Webber LS, Chiang YK, Berenson GSBlood pressure and echocardiographic measures in children: the Bogalusa Heart Study. Circulation. 1987;75:106–114.[PubMed][Google Scholar]
  • 16. Pontremoli R, Nicolella C, Viazzi F, Ravera M, Sofia A, Berruti V, Bezante GP, Del Sette M, Martinoli C, Sacchi G, Deferrari GMicroalbuminuria is an early marker of target organ damage in essential hyper-tension. Am J Hypertens. 1998;1(pt 1):430–438.[PubMed][Google Scholar]
  • 17. Report of the Second Task Force on Blood Pressure Control in Children–1987Task Force on Blood Pressure Control in Children: National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics. 1987;79:1–25.[PubMed][Google Scholar]
  • 18. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program: National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics. 1996;98(pt 1):649–658.[PubMed]
  • 19. Gruskin AB, Dabbagh S, Fleischmann LF, Apostol EL, Mattoo TK. Mechanisms of hypertension in childhood diseases. In: Barratt TM, Avner ED, Harmon W, editors. Pediatric Nephrology. 4th ed Williams & Wilkins; Baltimore, Md: 1999. pp. 987–1006. [PubMed]
  • 20. Norwood VFHypertension. Pediatr Rev. 2002;23:197–208.[PubMed][Google Scholar]
  • 21. Sorof JM, Poffenbarger T, Franco K, Portman REvaluation of white coat hypertension in children: importance of the definitions of normal ambulatory blood pressure and the severity of casual hypertension. Am J Hypertens. 2001;14(pt 1):855–860.[PubMed][Google Scholar]
  • 22. Kouidi E, Fahadidou-Tsiligiroglou A, Tassoulas E, Deligiannis A, Coats AWhite coat hypertension detected during screening of male adolescent athletes. Am J Hypertens. 1999;12(pt 1):223–226.[PubMed][Google Scholar]
  • 23. Bald MAmbulatory blood pressure monitoring in children and adolescents: current insights into a new technique. Minerva Pediatr. 2002;54:13–24.[PubMed][Google Scholar]
  • 24. Koch VH, Furusawa EA, Saito MI, Colli A, Ignes EC, Okay Y, Mion D., JrWhite coat hypertension in adolescents. Clin Nephrol. 1999;52:297–303.[PubMed][Google Scholar]
  • 25. Schettini C, Bianchi M, Nieto F, Sandoya E, Senra HAmbulatory blood pressure: normality and comparison with other measurements: Hyper-tension Working Group. Hypertension. 1999;34(pt 2):818–825.[PubMed][Google Scholar]
  • 26. Soergel M, Kirschstein M, Busch C, Danne T, Gellermann J, Holl R, Krull F, Reichert H, Reusz GS, Rascher WOscillometric twenty-four-hour ambulatory blood pressure values in healthy children and adolescents: a multicenter trial including 1141 subjects. J Pediatr. 1997;130:178–184.[PubMed][Google Scholar]
  • 27. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404–2410.[PubMed]
  • 28. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WBSerum uric acid, diuretic treatment and risk of cardio-vascular events in the Systolic Hypertension in the Elderly Program (SHEP) J Hypertens. 2000;18:1149–1154.[PubMed][Google Scholar]
  • 29. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta JMild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283:F1105–F1110.[PubMed][Google Scholar]
  • 30. Kannel WBMetabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987;114:413–419.[PubMed][Google Scholar]
  • 31. Brand FN, McGee DL, Kannel WB, Stokes J, 3rd, Castelli WPHyper-uricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol. 1985;121:11–18.[PubMed][Google Scholar]
  • 32. Rovda IuI, Kazakova LM, Plaksina EAParameters of uric acid metabolism in healthy children and in patients with arterial hypertension. Pediatriia. 1990;8:19–22.[PubMed][Google Scholar]
  • 33. Goldstein HS, Manowitz PRelation between serum uric acid and blood pressure in adolescents. Ann Hum Biol. 1993;20:423–431.[PubMed][Google Scholar]
  • 34. Torok E, Gyarfas I, Csukas MFactors associated with stable high blood pressure in adolescents. J Hypertens Suppl. 1985;3(suppl 3):S389–S390.[PubMed][Google Scholar]
  • 35. Gruskin ABThe adolescent with essential hypertension. Am J Kidney Dis. 1985;6:86–90.[PubMed][Google Scholar]
  • 36. Reaven GMThe kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis. 1997;30:928–931.[PubMed][Google Scholar]
  • 37. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GGSerum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93:817–821.[PubMed][Google Scholar]
  • 38. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu LPrognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 2001;37:1069–1074.[PubMed][Google Scholar]
  • 39. Rao GN, Corson MA, Berk BCUric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266:8604–8608.[PubMed][Google Scholar]
  • 40. Quiroz Y, Pons H, Gordon KL, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ, Rodriguez-Iturbe BMycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol. 2001;281:F38–F47.[PubMed][Google Scholar]
  • 41. Franco M, Tapia E, Santamaria J, Zafra I, Garcia-Torres R, Gordon KL, Pons H, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta JRenal cortical vasoconstriction contributes to development of salt-sensitive hyper-tension after angiotensin II exposure. J Am Soc Nephrol. 2001;12:2263–2271.[PubMed][Google Scholar]
  • 42. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe BSubtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346:913–923.[PubMed][Google Scholar]
  • 43. Keller J, Zimmer G, Mall G, Ritz E, Amann KNephron number in patients with primary hypertension. N Engl J Med. 2003;348:101–118.[PubMed][Google Scholar]
  • 44. Johnson RJ, Rodriguez-Iturbe B, Schreiner GF, Herrera-Acosta JHypertension: a microvascular and tubulointerstitial disease. J Hypertens. 2002;20(suppl 3):S1–S7.[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.